ASCO GU 2018: Ten-year final results of the TROG 03.04 (RADAR) randomised phase-III trial

Historical data from RTOG 92.02 and EORTC 22961 have shown that long-term androgen deprivation therapy (ADT) is more effective than short-term ADT in men undergoing radiotherapy for clinically localised intermediate or high risk prostate cancer. However, long-term ADT carries with it a range of side-effects including sexual dysfunction, weight gain, bone density loss, cognitive dysfunction, and sarcopenia, to name a few.
Uro Today